TB-500 Side Effects and Safety: What We Know in 2026

There are no published human clinical trials of TB-500, and the FDA’s July 2026 review found zero safety or effectiveness data in people. The agency highlighted unknown risks such as immune reactions, injection-site infections, and possible peptide impurities, while its adverse-event database contained no structured reports to guide doctors or patients. Anyone considering TB-500 should understand that every claimed benefit is extrapolated from small animal studies, and that prescription-grade compounded versions are not yet available-Rx.com plans to offer them through licensed providers and a 503A pharmacy (coming soon).

• No human trials of TB-500 are registered on ClinicalTrials.gov as of October 2026 (ClinicalTrials.gov).
• FDA’s 2026 Pharmacy Compounding Advisory Committee briefing found 0 clinical safety studies, 0 FAERS adverse-event reports, and only 2 food-complaint cases involving TB-500 (fda.gov).
• The peptide is not FDA-approved, and no product containing TB-500 appears in the FDA’s Drugs@FDA database (fda.gov).
• Research-use-only (RUO) vials sold online can contain bacterial endotoxins or the wrong peptide sequence, raising infection and treatment-failure risks.
• People with active cancer, immune disorders, or who are pregnant should avoid TB-500 until human safety data emerge, according to FDA reviewers’ theoretical concerns (fda.gov).

What TB-500 Is-and Why It Lacks FDA Approval

TB-500 is a synthetic seven-amino-acid fragment of thymosin β4, a 43-amino-acid human protein involved in tissue repair. The fragment (sequence Ac-LKKTETQ) is water-soluble and marketed for subcutaneous or intramuscular injection. FDA staff reviewers found no human safety studies for TB-500 and recommended against including it on the 503A bulks list for routine compounding (fda.gov).

Regulatory status: TB-500 is not an FDA-approved drug and cannot be legally sold as a dietary supplement. The newly issued “Interim Access Policy for Compounding Using Certain Peptides” lets 503A pharmacies compound TB-500 only for individual patients under strict quality and reporting conditions, but it does not grant FDA approval.

Rx.com plans to offer prescription compounded versions of TB-500 through U.S.-licensed providers and a 503A pharmacy (coming soon). Until then, buyers often turn to research-use-only suppliers-an option the FDA says falls completely outside its enforcement-discretion policy.

Why Side Effects Are Hard to Predict for TB-500

Side-effect profiles are usually built from phased human trials, FDA labeling, and post-marketing databases-none of which exist for TB-500. The absence of human pharmacokinetic data means experts cannot estimate:

Immune responses: Small peptides can trigger anti-drug antibodies, especially when aggregated or contaminated. The FDA flagged immunogenicity as a “significant risk” because no studies measured antibodies after TB-500 injections (fda.gov).

Dose-dependent toxicity: In rat studies, tendon strength improved, but organ toxicity was not tracked for more than four weeks. Without longer follow-up, potential kidney, liver, or reproductive effects remain unknown.

Tumor-growth concerns: Full-length thymosin β4 is over-expressed in some cancers and can promote angiogenesis. FDA reviewers noted this theoretical risk but cited no direct evidence in humans (fda.gov).

Reported and Theoretical Side Effects of TB-500

The only side effects documented in regulatory files come from animal models and two informal consumer complaints. Still, clinicians extrapolate several plausible risks:

1. Injection-site reactions: Redness, pain, or swelling may follow any subcutaneous or intramuscular shot, and compounded peptides can sting if the pH or osmolarity is off.

2. Infection: Peptide vials that bypass sterility testing can introduce skin bacteria, leading to cellulitis or abscesses. No FAERS reports were filed, but two FDA food-complaint cases linked TB-500+BPC-157 blends to unspecified “injection irritation” (fda.gov).

3. Immune reactions: Aggregated peptides may form particles that activate the complement system, causing rash or flu-like symptoms-an effect observed with some biologics.

4. Unwanted angiogenesis: In mouse models, thymosin β4 accelerates new blood-vessel growth. Theoretically, that could worsen diabetic retinopathy or feed a silent tumor.

5. Unknown reproductive effects: No fertility or teratogenic studies exist. FDA reviewers therefore recommend avoiding TB-500 in pregnancy and breastfeeding.

Contamination Risks With Research-Use-Only Vials

RUO vials are not manufactured under FDA’s current good manufacturing practices (cGMP). Independent lab audits presented at the FDA’s 2024 peptide workshop found that 27 % of sampled RUO peptide vials failed sterility tests and 14 % contained less than 90 % of the labeled peptide.

Common issues include:

• Endotoxin contamination that can trigger fever or septic shock
• Wrong sequence or truncated peptide, reducing effectiveness
• Residual solvents like trifluoroacetic acid (TFA) that irritate tissue

Compounded prescription TB-500 will have to meet USP ⟨797⟩ sterility and endotoxin limits, use validated raw materials, and carry a beyond-use date appropriate for peptide stability. Those safeguards are absent in gray-market products sold as “lab reagents.”

Who Should Avoid TB-500 Until More Is Known

The FDA briefing notes several groups at potentially higher risk from experimental peptides like TB-500:

Cancer patients or survivors: Because full-length thymosin β4 can promote tumor angiogenesis, experts recommend steering clear until more data clarify whether the fragment shares that risk.

Pregnant or breastfeeding women: No developmental or reproductive toxicity studies exist. The FDA explicitly lists unknown effects on a fetus as a safety gap (fda.gov).

People with autoimmune disease: Peptide aggregates could theoretically activate the immune system or form antibody complexes.

Anyone without access to prescription-grade compounding: RUO products carry higher contamination risks and provide no medical oversight. If your clinician believes a peptide might help you heal, ask about regulated alternatives such as BPC-157 or enroll in monitored studies instead.

For regulated access when available, see prescription peptides from Rx.com-Rx.com plans to offer compounded TB-500 through licensed providers and a 503A pharmacy (coming soon).